Want to see GB:DXRX full AI Analyst Report?
Top Page
Diaceutics
(LSE:DXRX)
Select Model
Select Model
Rating:60Neutral
Price Target:
151.00 p
▲(5.23% Upside)
Action:Reiterated
Date:08/29/26
The score is supported primarily by improving 2025 fundamentals and a strong, low-leverage balance sheet. Offsetting this are still-fragile operating profitability and an extremely high P/E, while technical signals are largely neutral and do not add meaningful positive momentum.
Positive Factors
Revenue Growth
Sustained revenue expansion indicates growing demand for Diaceutics’ diagnostics intelligence and services as precision-medicine therapies require broader biomarker testing adoption.
Negative Factors
Weak Operating Profitability
Near break-even earnings leave limited protection against execution or cost pressures. Continued operating losses would constrain reinvestment capacity and make durable profitability dependent on further scale and margin improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained revenue expansion indicates growing demand for Diaceutics’ diagnostics intelligence and services as precision-medicine therapies require broader biomarker testing adoption.
Read all positive factors
Diaceutics (DXRX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£124.20M
Dividend YieldN/A
Average Volume (3M)307.84K
Price to Earnings (P/E)1331.8
Beta (1Y)0.59
Revenue Growth19.53%
EPS GrowthN/A
CountryUK
Employees205
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)<0.01
Shares Outstanding85,154,360
10 Day Avg. Volume75,530
30 Day Avg. Volume307,840
Financial Highlights & Ratios
PEG Ratio-11.04
Price to Book (P/B)2.67
Price to Sales (P/S)2.82
P/FCF Ratio75.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£215.00Price Target Upside49.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.01
Revenue Forecast (FY)£46.72M
Diaceutics Business Overview & Revenue Model
Company Description
Diaceutics PLC, established in 2005 and headquartered in Belfast, UK, is a company dedicated to accelerating the commercialization of diagnostic solutions. It offers global pharmaceutical companies comprehensive data, advanced analytics, and imple...
How the Company Makes Money
Diaceutics primarily makes money by selling diagnostics-related intelligence and services to pharmaceutical and biotechnology companies that market or develop precision-medicine therapies requiring biomarker testing. Key revenue streams typically ...
Diaceutics Earnings Call Summary
Earnings Call Date:Sep 17, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:Sep 29, 2026
Earnings Call Sentiment Positive
The earnings call presented a mix of positive developments, particularly with revenue growth, high gross margins, and the strategic launch of the PMx solution, alongside record order book figures. However, challenges such as the increased EBITDA loss and decreased TCV were noted. The overall sentiment leans towards optimism, driven by strategic advancements and strong financial positioning.Positive Updates
Revenue Growth
Revenue increased to GBP 12.3 million, up 24% or 28% on a constant currency basis, with 55% of revenue now being subscription-based.
Negative Updates
EBITDA Loss
EBITDA loss widened to negative GBP 1.3 million compared to negative GBP 200,000 in June 2023.
Read all updates
Q2-2024 Updates
Positive
Negative
Revenue Growth
Revenue increased to GBP 12.3 million, up 24% or 28% on a constant currency basis, with 55% of revenue now being subscription-based.
Read all positive updates
Company Guidance
In the Q2 2024 earnings call for Diaceutics, CEO Ryan Keeling detailed significant advancements achieved in the first half of the year, particularly emphasizing the launch of their PMx solution. The company has expanded its lab network, notably integrating rare disease data and enhancing European data capabilities, all contributing to a robust and automated data pipeline. This automation, aided by AI, has streamlined data handling from extraction to customer delivery. The PMx solution, which emerged as a pivotal development, has transformed their approach by directly engaging physicians with patient data, boosting engagement and conversion rates. The financial health of the company is strong, with a 24% revenue increase to £12.3 million and a gross profit margin of 87%. Diaceutics aims to transition to a 70% subscription-led revenue model by 2025, with recurring revenues currently at 55%. The company also reported a record order book of £27.9 million, with plans to achieve profitability and free cash flow generation by 2025.Diaceutics Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
86
Very Positive
Cash Flow
58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 38.44M | 32.16M | 23.70M | 19.50M | 13.94M |
| Gross Profit | 26.12M | 28.27M | 19.71M | 14.04M | 10.57M |
| EBITDA | 6.08M | 2.77M | 2.36M | 3.61M | 2.35M |
| Net Income | 97.00K | -1.70M | -1.75M | 724.00K | 561.00K |
Balance Sheet | |||||
| Total Assets | 50.01M | 48.62M | 46.34M | 48.26M | 45.01M |
| Cash, Cash Equivalents and Short-Term Investments | 7.34M | 12.74M | 16.67M | 19.84M | 19.68M |
| Total Debt | 1.15M | 1.06M | 1.21M | 1.33M | 1.56M |
| Total Liabilities | 9.53M | 8.76M | 5.56M | 5.74M | 4.36M |
| Stockholders Equity | 40.48M | 39.86M | 40.79M | 42.51M | 40.65M |
Cash Flow | |||||
| Free Cash Flow | 1.43M | -3.98M | -3.54M | 278.00K | -5.03M |
| Operating Cash Flow | 1.50M | 651.00K | 1.31M | 5.15M | 570.00K |
| Investing Cash Flow | -6.45M | -4.03M | -4.21M | -4.87M | -5.60M |
| Financing Cash Flow | -333.00K | -64.00K | -239.00K | -132.00K | -270.00K |
Diaceutics Technical Analysis
Positive
143.50
Price Trends
141.67
Positive
150.04
Negative
150.30
Negative
Market Momentum
1.18
Negative
55.14
Neutral
73.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:DXRX, the sentiment is Positive. The current price of 143.5 is below the 20-day moving average (MA) of 144.70, above the 50-day MA of 141.67, and below the 200-day MA of 150.30, indicating a neutral trend. The MACD of 1.18 indicates Negative momentum. The RSI at 55.14 is Neutral, neither overbought nor oversold. The STOCH value of 73.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:DXRX.
Diaceutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | £108.66M | 53.72 | 3.01% | 4.36% | 2.73% | -65.94% | |
60 Neutral | £124.20M | 1,331.82 | 0.25% | ― | 19.53% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £22.08M | -1.26 | -1044.57% | ― | 65.60% | 74.84% | |
48 Neutral | £12.50M | -0.49 | -104.73% | ― | -56.10% | 41.10% | |
40 Underperform | £18.14M | -0.33 | -631.25% | ― | ― | ― | |
38 Underperform | £15.46M | -0.29 | -451.74% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
GB:DXRX
Diaceutics
148.50
6.50
4.58%
GB:CLBX
ANGLE plc
1.10
-4.65
-80.87%
GB:EKF
EKF Diagnostics Holdings
25.25
-5.85
-18.81%
GB:GDR
Genedrive
1.35
0.93
221.43%
GB:OBD
Oxford BioDynamics
0.12
-0.37
-76.04%
GB:RENX
Renalytix
4.15
-1.70
-29.06%
Diaceutics Corporate Events
Business Operations and Strategy
Diaceutics and PCC Launch NGS Study to Boost Confidence in Cancer Diagnostics
Positive
Aug 20, 2026
Diaceutics PLC and the Precision Cancer Consortium have launched an NGS Concordance Study to evaluate how consistently genomic variants are detected across next-generation sequencing panels and platforms used in routine U.S. clinical practice. The...
Business Operations and StrategyRegulatory Filings and Compliance
Diaceutics boosts employee share incentives and updates total voting rights
Positive
Aug 4, 2026
Diaceutics PLC has expanded its employee share ownership framework, with trustees of its 2020 Employee Benefit Trust purchasing ordinary shares on behalf of three senior executives under the UK and Global Share Incentive Plan. The company is match...
Business Operations and StrategyFinancial Disclosures
Diaceutics boosts recurring revenue and order book, sharpening 2026 outlook
Positive
Jul 29, 2026
Diaceutics reported strong first-half 2026 performance, with revenue up 22% on a constant currency basis to £17.5 million and Annual Recurring Revenue surging 75% to £28.8 million. The company’s recurring revenue now accounts for a...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Diaceutics updates on executive share incentive purchases and expanded share capital
Positive
Jul 3, 2026
Diaceutics has reported that trustees of its 2020 Employee Benefit Trust have been purchasing ordinary shares on behalf of senior executives under its UK and Global Share Incentive Plans, with the company matching employee purchases on a 1:1 basis...
Stock BuybackShareholder Meetings
Diaceutics Wins Shareholder Backing for All AGM Resolutions
Positive
Jun 25, 2026
Diaceutics PLC reported that shareholders approved all resolutions at its latest Annual General Meeting, underscoring strong investor backing for the company’s governance and strategic direction. The meeting saw solid support for the company...
Business Operations and StrategyRegulatory Filings and Compliance
Diaceutics Updates Share Incentive Awards and Total Voting Rights
Neutral
Jun 1, 2026
Diaceutics has reported ongoing purchases of ordinary shares for senior executives under its UK and Global Share Incentive Plan, with trustees acquiring shares on behalf of key PDMRs and the company matching these on a 1:1 basis through conditiona...
Financial DisclosuresRegulatory Filings and ComplianceShareholder Meetings
Diaceutics Posts 2025 Annual Report and Sets Date for 2026 AGM
Neutral
May 29, 2026
Diaceutics PLC has distributed its Annual Report for the year ended 31 December 2025 to shareholders, alongside the notice of its 2026 Annual General Meeting. The AGM is scheduled for 25 June 2026 in Belfast, with the report and meeting materials ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.